20 April 2026
Latham & Watkins Advises on Alamar Biosciences’ Upsized US$191.3 Million Initial Public Offering
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Ross McAloon Lead | Latham & Watkins LLP | Partner | Capital Markets | Orange County/Bay Area |
| Raul Gonzalez Cassarubias | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Lexi Zintel | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Skyler Ligon | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 191m (US$191.3 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Alamar Biosciences, Inc. (Issuer)